Cancer Chemotherapy Center

Innovating safe and effective anti-cancer drugs and treatments

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer　 More

To identify molecular targets and compounds for cancer therapy

We discover and develop the novel molecular-targeted drugs by using Cancer Cell Informatics.

Telomeres, cell immortality and cancer stemness as therapeutic targets

We promote genome science-driven research for targeted therapy and personalized medicine

We focus the research between clinical samples and imaging the molecular target

Yoshitake, H., Negoto, T., Moritsubo, M., Furuta, T., Jo, M., Hirota, T., Sakata, K., Nakamura, H. and Morioka, M.

Chromosomal instability is associated with paradoxical cGAS upregulation and impaired STING signaling shaping the immune microenvironment in glioblastoma.
Neurooncol. Adv., vdag179 (2026)
Hara, T., Meng, S., Konno, M., Nishida, N., Koseki, J., Meguro, K., Kawano, Y., Morie, T., Dan, S., Satoh, T., Akai, S., Tsujikawa, K., Eguchi, H., Mori, M., Miura, Y., Nishiyama, N. and Ishii, H.

Identification of novel small-molecule inhibitors targeting KDM5B and evaluation of their antitumour effects.
Cancer Med., 15, e72058 (2026)
Ozaki, H., Sasaki, N. and Kitajima, S.

An aminoacyl-tRNA synthetase governs dsRNA-mediated trade-off between longevity and innate immunity.
Mol. Cell, 86, 2237-2239 (2026)
Kamakura, N., Jo, M., Takahashi, M. and Hirota, T.

Targeting cell cycle vulnerabilities in cancers: Emerging strategies for therapeutic development.
Cancer Sci., in press (2026)
Tanaka, T., Fujitani, M., Taoka, M., Shimomura, I., Okawa, S., Mori, S., Kuribayashi, T., Nishimura, J., Nishimura, T., Morita, A., Hara, N., Ninomiya, K., Makimoto, G., Higo, H., Rai, K., Ichihara, E., Tomida, S., Hotta, K., Togashi, Y., Maeda, Y., Kiura, K., Katayama, R. and Ohashi, K.

Afatinib overcomes osimertinib resistance via Egfr v804f mutation in a syngeneic Egfr-mutant lung cancer mouse model.
Cancer Sci., in press (2026)